Back to results
US 2014/0349940 A1Published application
Prevention and reduction of blood loss
AssigneeDyax Corp.
InventorsRobert C. Ladner, Arthur C. Ley, Shirish Hirani, Anthony Williams
Life of this patent
Estimating the term…
Abstract
Methods are described for preventing or reducing ischemia and/or systemic inflammatory response in a patient such as perioperative blood loss and/or systemic inflammatory response in a patient subjected to cardiothoracic surgery, e.g. coronary artery bypass grafting and other surgical procedures, especially when such procedures involve extra-corporeal circulation, such as cardiopulmonary bypass.
Claims2
A method for reducing blood loss in a patient comprising administering to the patient a composition comprising a polypeptide comprising the amino acid sequence:
- Xaa1 Xaa2 Xaa3 Xaa4 Cys Xaa6 Xaa7 Xaa8 Xaa9 Xaa10 Xaa11 Gly Xaa13 Cys Xaa15 Xaa16 Xaa17 Xaa18 Xaa19 Xaa20 Xaa21 Xaa22 Xaa23 Xaa24 Xaa25 Xaa26 Xaa27 Xaa28 Xaa29 Cys Xaa31 Xaa32 Phe Xaa34 Xaa35 Gly Gly Cys Xaa39 Xaa40 Xaa41 Xaa42 Xaa43 Xaa44 Xaa45 Xaa46 Xaa47 Xaa48 Xaa49 Xaa50 Cys Xaa52 Xaa53 Xaa54 Cys Xaa56 Xaa57 Xaa58 (SEQ ID NO:1), wherein
- Xaa1, Xaa2, Xaa3, Xaa4, Xaa56, Xaa57 or Xaa58 are each individually an amino acid or absent;
- Xaa10 is Asp;
- Xaa11 is an amino acid selected from the group consisting of:
- Asp, Gly, Ser, Val, Asn, Ile, Ala and Thr;
- Xaa13 is an amino acid selected from the group consisting of:
- Arg, His, Pro, Asn, Ser, Thr, Ala, Gly, Lys and Gln;
- Xaa15 is an amino acid selected from the group consisting of:
- Arg, Lys, Ala, Ser, Gly, Met, Asn and Gln;
- Xaa16 is an amino acid selected from the group consisting of:
- Ala, Gly, Ser, Asp and Asn;
- Xaa17 is an amino acid selected from the group consisting of:
- Ala, Asn, Ser, Ile, Gly, Val, Gln and Thr;
- Xaa18 is an amino acid selected from the group consisting of:
- His, Leu, Gln and Ala;
- Xaa19 is an amino acid selected from the group consisting of:
- Pro, Gln, Leu, Asn and Ile;
- Xaa21 is an amino acid selected from the group consisting of:
- Trp, Phe, Tyr, His and Ile;
- Xaa22 is an amino acid selected from the group consisting of:
- Tyr and Phe;
- Xaa23 is an amino acid selected from the group consisting of:
- Tyr and Phe;
- Xaa31 is an amino acid selected from the group consisting of:
- Glu, Asp, Gln, Asn, Ser, Ala, Val, Leu, Ile and Thr;
- Xaa32 is an amino acid selected from the group consisting of:
- Glu, Gln, Asp Asn, Pro, Thr, Leu, Ser, Ala, Gly and Val;
- Xaa34 is an amino acid selected from the group consisting of:
- Thr, Ile, Ser, Val, Ala, Asn, Gly and Leu;
- Xaa35 is an amino acid selected from the group consisting of:
- Tyr, Trp and Phe;
- Xaa39 is an amino acid selected from the group consisting of:
- Glu, Gly, Ala, Ser and Asp;
- Xaa40 is an amino acid selected from the group consisting of:
- Gly and Ala;
- Xaa43 is an amino acid selected from the group consisting of:
- Asn and Gly;
- Xaa45 is an amino acid selected from the group consisting of:
- Phe and Tyr;
- and wherein the polypeptide inhibits kallikrein.
37 more elements
2-49. (canceled)
Dependencies are inferred from the claim text.